Please assess the completion status of the following clinical trial:

Trial Title: Study of the Efficacy and Safety of the Combination of Two FDA Approved Oral Medications, Nebivolol and Valsartan for Treatment of Stage 1 or 2 Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 8.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female outpatients of age 18 years or above~* Patients diagnosed with stage 1 or stage 2 essential hypertension~* Normal physical examination findings, electrocardiogram (ECG) results and chest x-ray; or abnormal findings judged by the Investigator to be not clinically significant~Exclusion Criteria:~* Secondary hypertension or severe hypertension~* Clinically significant cardiovascular disease or heart failure~* Clinical significant respiratory disease that would prohibit the use of a beta blocker~* A medical contraindication to discontinuing a current antihypertensive therapy~* History of Type 1 diabetes mellitus~* History of Severe Mental Illness except mild depression

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nebivolol and Valsartan Fixed Dose Combination 1 (Type: EXPERIMENTAL): Fixed Dose Combination Nebivolol 5 mg and Valsartan 80 mg
- Nebivolol and Valsartan Fixed Dose Combination 2 (Type: EXPERIMENTAL): Fixed Dose Combination Nebivolol 5 mg and Valsartan 160 mg
- Nebivolol and Valsartan Fixed Dose Combination 3 (Type: EXPERIMENTAL): Fixed Dose Combination Nebivolol 10 mg and Valsartan 160 mg
- Nebivolol Low Dose (Type: EXPERIMENTAL): Nebivolol Monotherapy 5 mg
- Nebivolol High Dose (Type: EXPERIMENTAL): Nebivolol Monotherapy 20 mg
- Valsartan Low Dose (Type: EXPERIMENTAL): Valsartan Monotherapy 80 mg
- Valsartan High Dose (Type: EXPERIMENTAL): Valsartan Monotherapy 160 mg
- Placebo (Type: PLACEBO_COMPARATOR): Dose Matched placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).